CA2479835C - An ephrin-b receptor protein involved in carcinoma - Google Patents

An ephrin-b receptor protein involved in carcinoma Download PDF

Info

Publication number
CA2479835C
CA2479835C CA2479835A CA2479835A CA2479835C CA 2479835 C CA2479835 C CA 2479835C CA 2479835 A CA2479835 A CA 2479835A CA 2479835 A CA2479835 A CA 2479835A CA 2479835 C CA2479835 C CA 2479835C
Authority
CA
Canada
Prior art keywords
polypeptide
ccmp
expression
nucleic acid
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2479835A
Other languages
English (en)
French (fr)
Other versions
CA2479835A1 (en
Inventor
Robert Simon Boyd
Graham Charles Fletcher
Lindsey Jane Hudson
Sonal Patel
Jonathan Alexander Terrett
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB SA
Original Assignee
UCB SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB SA filed Critical UCB SA
Publication of CA2479835A1 publication Critical patent/CA2479835A1/en
Application granted granted Critical
Publication of CA2479835C publication Critical patent/CA2479835C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57515—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the breast
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2479835A 2002-04-09 2003-04-09 An ephrin-b receptor protein involved in carcinoma Expired - Fee Related CA2479835C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0208089.3 2002-04-09
GBGB0208089.3A GB0208089D0 (en) 2002-04-09 2002-04-09 Protein
PCT/GB2003/001593 WO2003087841A2 (en) 2002-04-09 2003-04-09 An ephrin-b receptor protein involved in carcinoma

Publications (2)

Publication Number Publication Date
CA2479835A1 CA2479835A1 (en) 2003-10-23
CA2479835C true CA2479835C (en) 2013-10-01

Family

ID=9934469

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2479835A Expired - Fee Related CA2479835C (en) 2002-04-09 2003-04-09 An ephrin-b receptor protein involved in carcinoma

Country Status (7)

Country Link
US (2) US7655426B2 (enExample)
EP (1) EP1497659A2 (enExample)
JP (2) JP2005522229A (enExample)
AU (1) AU2003227862B2 (enExample)
CA (1) CA2479835C (enExample)
GB (1) GB0208089D0 (enExample)
WO (1) WO2003087841A2 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2610685A1 (en) 2005-06-03 2006-12-14 Novartis Vaccines And Diagnostics, Inc. Methods of treating, diagnosing or detecting cancer using an ephb3 modulator
RU2009107707A (ru) 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
MX2009006034A (es) * 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
US20100041048A1 (en) * 2008-07-31 2010-02-18 The Johns Hopkins University Circulating Mutant DNA to Assess Tumor Dynamics
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4233782A1 (de) * 1992-10-07 1994-04-14 Chemotherapeutisches Forschungsinstitut Georg Speyer Haus Klonierung eines neuen Mitgliedes der Familie der Rezeptor-Protein-Tyrosin-Kinasen
US5506205A (en) * 1993-11-24 1996-04-09 Ono Pharmaceutical Co., Ltd. Polypeptide of protein p140 and DNAs encoding it
US5457048A (en) 1993-12-03 1995-10-10 La Jolla Cancer Research Foundation Eph-related tyrosine kinases, nucleotide sequences and methods of use
EP0756627A1 (en) 1994-04-15 1997-02-05 Amgen Inc. Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
AU2001243142A1 (en) 2000-02-03 2001-08-14 Hyseq, Inc. Novel nucleic acids and polypeptides
WO2001072833A2 (en) * 2000-03-27 2001-10-04 Bayer Aktiengesellschaft Human ephrin-like receptor
AUPQ909100A0 (en) * 2000-07-28 2000-08-24 Ludwig Institute For Cancer Research A method for diagnosis and treatment
US20030077568A1 (en) 2000-09-15 2003-04-24 Gish Kurt C. Methods of diagnosis of colorectal cancer, compositions and methods of screening for colorectal cancer modulators
AU2002314433A1 (en) 2001-07-02 2003-01-21 Licentia Ltd. Ephrin-tie receptor materials and methods
US20070087406A1 (en) * 2005-05-04 2007-04-19 Pei Jin Isoforms of receptor for advanced glycation end products (RAGE) and methods of identifying and using same

Also Published As

Publication number Publication date
GB0208089D0 (en) 2002-05-22
WO2003087841A3 (en) 2004-02-26
JP2005522229A (ja) 2005-07-28
AU2003227862B2 (en) 2008-08-28
US20110150877A1 (en) 2011-06-23
US7655426B2 (en) 2010-02-02
EP1497659A2 (en) 2005-01-19
CA2479835A1 (en) 2003-10-23
WO2003087841A2 (en) 2003-10-23
US20050260209A1 (en) 2005-11-24
JP2010101901A (ja) 2010-05-06
AU2003227862A1 (en) 2003-10-27

Similar Documents

Publication Publication Date Title
AU2008207533B2 (en) Methods for diagnosis and treatment of epithelial-derived cancers
US20110150877A1 (en) Ephrin-b receptor protein involved in carcinoma
AU2003249072B2 (en) PTK7 protein involvement in carcinoma
US20060088537A1 (en) Protein involved in cancer
CA2736170A1 (en) Methods for diagnosing and treating cancers
US20090258019A1 (en) Diagnosis of carcinoma using RAIG1 polypeptides
WO2003075014A2 (en) Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11
US7297760B2 (en) Cancer associated protein
US20040166517A1 (en) Cancer associated protein
GB2388113A (en) B-cell malignancy-associated protein
WO2005023300A2 (en) Method for treating, preventing and/or diagnosing cancer, related to the use of mal2 polypeptide
WO2005049066A2 (en) Use of dudulin2 for the treatment or prophylaxis of lung cancer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20170410